Random is ed prostate cancer screening trial: 20 Year follow-up

BMJ

Volumn 342, Issue 7803, 2011, Pages

  Sandblom, Gabriel ^a   Varenhorst, Eberhard ^b   Rosell, Johan ^b   Löfman, Owe ^c   Carlsson, Per ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SWEDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY DIAGNOSIS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RISK FACTOR;

AGED; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN;

EID: 79955430532     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1539     Document Type: Article

References (25)

1. Bill-Axelsson A, Holmberg L, Filén F, RuutuM, GarmoH, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. J Natl Cancer Inst 2008;100:1144-54.
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al for the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
3. Schröder FH,Hugosson J, RoobolMJ, Tammela TL, Ciatto S, Nelen V, et al: ERSPC Investigators. Screening and prostate-cancermortality in a randomized European study.N Engl J Med 2009;360:1320-8.
4. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomized populationbased prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
5. Pedersen KV, Carlsson P, Varenhorst E, Löfman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990;300:1041-4. (Pubitemid 20149312)
6. Varenhorst E, Berglund K, Löfman O, Pedersen KV. Inter-observer variation in assessment of the prostate by digital rectal examination. Br J Urol 1993;72:173-6. (Pubitemid 23252595)
7. Varenhorst E, Carlsson P, Capik E, Löfman O, Pedersen KV. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol 1992;31:815-21. (Pubitemid 23089752)
8. Carlsson P, Pedersen KV, Varenhorst E. Costs and benefits of early detection of prostatic cancer. Health Policy 1990;16:241-53.
9. Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004;46:717-23. (Pubitemid 39488400)
10. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
11. Socialstyrelsen. Swedish Central Death Register. 2010. www.socialstyrelsen.se/english/international/statistics.
12. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9. (Pubitemid 38725420)
13. Barlow L, Westerberg K, Holmberg L, TalbäckM. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol 2009;48:27-33.
14. Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden-an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003;37:112-9. (Pubitemid 36535228)
15. Sandblom G, Ladjevardi S, Garmo H, Varenhorst E. Impact of PSA at diagnosis on the relative survival of 28 531 men with localized carcinoma of the prostate. Cancer 2008;112:813-9. (Pubitemid 351240575)
16. Stattin P, Johansson R, Damber JE, HellströmM, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden-study from the National Prostate Cancer Register. Scand J Urol Nephrol 2003;37:461-5. (Pubitemid 38091158)
17. Sennfält, Carlsson P, Varenhorst E. Diffusion of and economic consequences of health technologies in prostate cancer in Sweden 1991-2002. Eur Urol 2006;49:1028-34. (Pubitemid 43674018)
18. Britton M, Jonsson E. Impact of health technology assessments. Int J Technol Assess Health Care 2002;18:824-31.
19. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann InternMed 2008;149:192-9.
20. Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E: South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352-7.
21. Schröder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 2010;58:46-52.
22. Heijnsdijk EAM, der Kinderen A, Wever EM, Draisma G, RoobolMJ, de Koning HJ. Overdetection, overtreatment and costs in prostatespecific antigen screening for prostate cancer. Br J Cancer 2009;101:1833-8.
23. Draisma G, Boer R, Otto SJ, van der Cruijsen IW,Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78. (Pubitemid 36833878)
24. Albertsen PC. The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis. Urology 2010;75:399-405.
25. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.